News Releases

Printer friendly version

Protox Therapeutics to be featured on CEO Clips on The Biography Channel

Monday, March 27, 2006 - Vancouver, British Columbia - CEO Clips, a series of two minute corporate profiles on Canadian companies, will feature Protox Therapeutics Inc. (TSX-V: PRX) on The Biography Channel beginning March 27, 2006 at various times throughout the day and evening. It will also be posted on Yahoo Finance Canada and can be viewed online at www.protoxtherapeutics.com.

About The Biography Channel:
Over half of Canadians in digital households watch The Biography Channel, according to the Roper Report 2005. The Biography Channel finished #1 in awareness, viewer ship and importance to the enjoyment of cable in the latest Beta Research Subscriber study of digital cable subscribers and can currently be viewed in 800,000 Canadian homes.

About Protox Therapeutics:
Protox Therapeutics is a product-focused development-stage company and a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other diseases. Through the company's PORxin™ technology platform, therapeutic candidates are generated by engineering the naturally occurring protein, pro-aerolysin. These proteins become potent anti-cancer agents when activated at a tumor site by specific proteases produced by cancer cells. Once activated, the drug punches holes in the cancer cells causing the contents to leak out and ultimately, cell death. Protox has received clearance from the FDA to commence Phase 1 clinical trials with the lead compound, PRX302, for the treatment of localized prostate cancer. PRX302 is also being developed for treatment of benign prostatic hyperplasia.

Link to the webcast replay of the CEO Clips spot on the Biography Channel.

For more information, contact:
Elayne Wandler
Director, Investor Relations and Corporate Communications, Protox Therapeutics Inc.
Direct: 604-688-4369
Cell: 778-865-0172
Fax: 604-688-0173
ewandler@protoxtherapeutics.com

What's New

June 2 2010
Protox Announces Positive Six Month Phase 2B BPH Results

June 1, 2010
Protox to Present Phase 2B BPH Data at the Annual Meeting of the American Urological Association

May 13, 2010
Protox Reports First Quarter 2010 Financial Results

April 29, 2010
Protox Signs $75 Million License Agreement with Kissei for Commercialization of PRX302 in Japan for BPH and Prostate Disease

 

Events

January 11, 2010 - 8:45 am ET
Protox Therapeutics Conference Call - Webcast Link

 

Stock Quote

LAST TRADE:$0.39
TRADE TIME:3:53PM EST
CHANGE:$0.00 (0.00%)
PREV CLOSE: $0.39
OPEN:$0.39
BID:$0.385
ASK:$0.39